PolyPeptide Group AG (0AAJ.L)

29,21 -0,09 (-0,32%) Alla chiusura: 07:06PM BST

PolyPeptide Group AG

Neuhofstrasse 24
Baar 6340
Switzerland
41 435 020 580
https://www.polypeptide.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 1.273

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Klaus Peter Wilden	Executive Chair	305,77k	N/D	1957
Mr. Juan Jose Gonzalez	Chief Executive Officer	1,17M	N/D	1972
Mr. Marc Augustin	Chief Financial Officer	N/D	N/D	1972
Mr. Jens Fricke	Director of Global Operations	N/D	N/D	1965
Rene Vestergaard	Director of Corporate Finance	N/D	N/D	N/D
Mr. Olivier Ludemann-Hombourger	Director Global Innovation & Technology	N/D	N/D	1972
Ms. Christina Del Vecchio	General Counsel & Corporate Secretary	N/D	N/D	1978
Mr. Neil James Thompson	Director of Global Sales & Marketing	N/D	N/D	1972
Ms. Monika Casanova	Chief Human Resources Officer	N/D	N/D	1979
Christophe Chevalier	Head of Technical Department - Braine	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Governance aziendale

L'ISS Governance QualityScore di PolyPeptide Group AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.